What does the research say about Cardio-oncology?

Q: What does the research say about Cardio-oncology?

The scientific consensus on Cardio-oncology is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims.

Cardiology

Cardio-oncology

Cardiovascular effects of cancer therapy

Emerging pathwayAlso known as: onco-cardiology, cancer cardiotoxicity, chemotherapy heart

979

Clinical questions

201

Evidence-backed

100

Claims analyzed

Followers

What the evidence says about Cardio-oncology

Synthesized from 201 evidence-backed clinical questions linked to this topic — 34 supporting the intervention, 53 against the intervention, 7 still contested.

Where the evidence lands

201 questions

The placed evidence leans toward harm

Favor benefit

17% of all

Favor harm

26% of all

Benefit7 contestedHarm

107 more (53%) still untested — not placed on the axis.

Weak For3417%

New research on Cardio-oncology

Long-term bleeding events post-percutaneous coronary intervention in patients with malignancy with and without anticoagulant therapy

Cardiovascular Intervention and Therapeutics — Otsuka Y — Jun 2025

Preoperative Exercise Echocardiography and Perioperative Cardiovascular Outcomes in Elderly Patients Undergoing Cancer Surgery

The American Journal of Geriatric Cardiology — Shoyeb A — Nov 2006

Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis

Medicine — Han D — Jan 2020

Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review

Hellenic Journal of Cardiology — Karvelas G — Mar 2018

Targeting the Angiopoietin/Tie2 Pathway: Cutting Tumor Vessels With a Double-Edged Sword?

Journal of Clinical Oncology — Cascone T — Dec 2011

Cardiovascular drugs and cancer: of competing risk, smallpox, Bernoulli, and d'Alembert

European Heart Journal — Messerli F — Jul 2012

Takotsubo Cardiomyopathy as Epiphenomenon of Cardiotoxicity in Patients With Cancer: A Meta-summary of Case Reports

Journal of Cardiovascular Pharmacology — Carbone A — May 2021

Pegylated liposomal doxorubicin: Pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (Review)

Oncology Reports — Orditura M — Sep 2004

Thrombosis and Cancer: Emerging Data for the Practicing Oncologist

American Society of Clinical Oncology Educational Book — Lyman G — Jan 2013

Exercise Effects on HRV in Cancer Patients

International Journal of Sports Medicine — Niederer D — Aug 2012

Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer.

Journal of Clinical Oncology — Schwartz C — Oct 1993

Heart of the matter: reverse takotsubo syndrome in an anthracycline-exposed oncology patient

BMJ Case Reports — Voit J — Oct 2018

Evidence brief: Cardio-oncology

Cardio-oncology (also known as onco-cardiology, cancer cardiotoxicity, chemotherapy heart). Cardiovascular effects of cancer therapy

Synapse tracks 6 specific clinical questions in Cardio-oncology, each synthesized independently from its own trial evidence. They include: "Does immune checkpoint inhibitors vs placebo improve outcomes in cancer therapy-related cardiovascular toxicity?"; "Does anticoagulants vs placebo improve outcomes in Malignant Neoplasms?"; "Does sodium-glucose cotransporter-2 inhibitors vs immune checkpoint inhibitors improve All-Cause Mortality in Malignant Neoplasms?"; "Does carvedilol vs doxorubicin improve Cardiac Index in Malignant neoplasm of breast?"; "Does candesartan vs doxorubicin improve Cardiac Index in Malignant neoplasm of breast?".

As of 2026-09-08, the scientific consensus on Cardio-oncology is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.

This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/cardio-oncology.

Deterministic synthesis from Synapse's enriched corpus — 131 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.

Cardio-oncology

What the evidence says about Cardio-oncology

Where the evidence lands

Strength of that evidence

Actively debated